Clofazimine for the treatment of multidrug-resistant tuberculosis: Prospective, multicenter, randomized controlled study in China

Clinical Infectious Diseases

Volumn 60, Issue 9, 2015, Pages 1361-1367

  Tang, Shenjie ^a   Yao, Lan ^b   Hao, Xiaohui ^b   Liu, Yidian ^b   Zeng, Linhai ^b   Liu, Gang ^c   Li, Mingwu ^d   Li, Fujian ^e   Wu, Meiying ^f   Zhu, Yousheng ^g   Sun, Hua ^h   Gu, Jin ^b   Wang, Xiafang ^f   Zhang, Zhanjun ^b  

^a CAPITAL MEDICAL UNIVERSITY   (China)

^b TONGJI UNIVERSITY SCHOOL OF MEDICINE   (China)

^c Anhui Chest Hospital ^*  (China)

^d the Third People s Hospital of Kunming   (China)

^e Hangzhou Red Cross Hospital   (China)

^f The Affiliated Infectious Diseases Hospital of Soochow University   (China)

^g Tongling People's Hospital   (China)

^h Shanghai Minhang District Hospital   (China)

Author keywords

Clofazimine; Efficacy; Multidrug resistant tuberculosis; Tolerability

Indexed keywords

CLOFAZIMINE; TUBERCULOSTATIC AGENT;

ADULT; ANEMIA; ANTIBIOTIC SENSITIVITY; ARTICLE; CHINA; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; GASTROINTESTINAL DISEASE; HEARING IMPAIRMENT; HEART ARRHYTHMIA; HUMAN; HYPOKALEMIA; ICHTHYOSIS; LEUKOPENIA; LIVER INJURY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MULTIDRUG RESISTANT TUBERCULOSIS; NAUSEA AND VOMITING; OPTIC NERVE DISEASE; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; RASH; SKIN DISCOLORATION; THROMBOCYTOPENIA; TINNITUS; TREATMENT OUTCOME; ADOLESCENT; CLINICAL TRIAL; DRUG EFFECTS; ISOLATION AND PURIFICATION; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; MIDDLE AGED; MYCOBACTERIUM TUBERCULOSIS; SPUTUM; TUBERCULOSIS, MULTIDRUG-RESISTANT; TUBERCULOSIS, PULMONARY; YOUNG ADULT;

ADOLESCENT; ADULT; ANTITUBERCULAR AGENTS; CHINA; CLOFAZIMINE; FEMALE; HUMANS; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; MYCOBACTERIUM TUBERCULOSIS; SPUTUM; TREATMENT OUTCOME; TUBERCULOSIS, MULTIDRUG-RESISTANT; TUBERCULOSIS, PULMONARY; YOUNG ADULT;

EID: 84928910979     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/civ027     Document Type: Article

References (32)

1. World Health Organization. Global tuberculosis report 2013. WHO/HTM/TB/2013.11. Geneva, Switzerland: WHO, 2013.
2. Gandhi NR, Nunn P, Dheda K, et al. Multidrug-resistant and extensively drug-resistant tuberculosis: a threat to global control of tuberculosis. Lancet 2010; 375:1830-43.
3. World Health Organization. Multidrug and extensively drug-resistant TB (M/XDR-TB):2010 global report on surveillance and response. WHO/HTM/TB/2010.3. Geneva, Switzerland: WHO, 2010.
4. Tang SJ, Tan SY, Yao L, et al. Risk factors for poor treatment outcomes in patients with MDR-TB and XDR-TB in China: retrospective multi-center investigation. PLoS One 2013; 8:e82943.
5. Zhao YL, Xu SF, Wang LX, et al. National survey of drug-resistant tuberculosis in China. N Engl J Med 2012; 366:2161-70.
6. Ahuja SD, Ashkin D, Avendano M, et al. Multidrug resistant pulmonary tuberculosis treatment regimens and patient outcomes: an individual patient data meta-analysis of 9, 153 patients. PLoS One 2012; 9: e1001300.
7. Jagannath C, Reddy M, Kailasam S, et al. Chemotherapeutic activity of clofazimine and its analogues against Mycobacterium tuberculosis. In vitro, intracellular, and in vivo studies. Am J Resp Crit Care Med 1995; 151:1083-6.
8. Dooley KE, Obuku EA, Durakovic N, et al. World Health Organization group 5 drugs for the treatment of drug-resistant tuberculosis: unclear efficacy or untapped potential? J Infect Dis 2013; 207:1352-8.
9. Barry VC, Belton JG, Conalty ML, et al. A new series of phenazines (ri-mino-compounds) with high antituberculosis activity. Nature 1957; 179:1013-5.
10. Barry VC, Buggle K, Byrne J, Conalty ML, Winder F. Absorption, distribution and retention of the riminocompounds in the experimental animal. Ir J Med Sci 1960; 416:345-52.
11. Cho SH, Warit S, Wan B, et al. Low oxygen-recovery assay for high-throughput screening of compounds against nonreplicating Mycobacterium tuberculosis. Antimicrob Agents Chemother 2007; 51:1380-5.
12. Venkatesan K, Deo N, Gupta UD. Tissue distribution and deposition of clofazimine in mice following oral administration with or without iso-niazid. Arzneimittelforschung 2007; 57:472-4.
13. Reddy VM, O'Sullivan JF, Gangadharam PR. Antimycobacterial activities of riminophenazines. J Antimicrob Chemother 1999; 43:615-23.
14. Xu J, Lu Y, Fu L, et al. In vitro and in vivo activity of clofazimine against Mycobacterium tuberculosis persisters. Int J Tuberc Lung Dis 2012; 16:1119-25.
15. Grosset JH, Tyagi S, Almeida DV, et al. Assessment of clofazimine activity in a second-line regimen for tuberculosis in mice. Am J Respir Crit Care Med 2013; 188:608-12.
16. Cholo MC, Steel HC, Fourie PB, et al. Clofazimine: current status and future prospects. J Antimicrob Chemother 2012; 67:290-8.
17. World Health Organization. Guidelines for the programmatic management of drug-resistant tuberculosis, 2011 update. WHO/HTM/TB/2011.6. Geneva, Switzerland: WHO, 2013.
18. World Health Organization. Guidelines for the programmatic management of drug-resistant tuberculosis: emergency update 2008. Geneva, Switzerland: WHO, 2008.
19. Goble M, Iseman MD, Madsen LA, et al. Treatment of 171 patients with pulmonary tuberculosis resistant to isoniazid and rifampin. N Engl J Med 1993; 328:527-32.
20. Geerligs WA, Van Altena R, De Lange WCM, et al. Multidrug-resistant tuberculosis: long-term treatment outcome in the Netherlands. Int J Tuberc Lung Dis 2000; 4:758-64.
21. Van Deun A, Maug A, Salim M, et al. Short, highly effective, and inexpensive standardized treatment of multidrug-resistant tuberculosis. Am J Resp Crit Care Med 2010; 182:684-92.
22. Mitnick CD, Shin SS, Seung KJ, et al. Comprehensive treatment of extensively drug-resistant tuberculosis. N Engl J Med 2008; 359:563-74.
23. Gopal M, Padayatchi N, Metcalfe JZ, O'Donnell MR. Systematic review of clofazimine for the treatment of drug-resistant tuberculosis. Int J Tuberc Lung Dis 2013; 17:1001-7.
24. Chang KC, Yew WW, Tam CM, Leung CC WHO group 5 drugs and difficult multidrug-resistant tuberculosis: a systematic review with cohort analysis and meta-analysis. Antimicrob Agents Chemother 2013; 57:4097-104.
25. Mukherjee JS, Rich ML, Socci AR, et al. Programmes and principles in treatment of multidrug-resistant tuberculosis. Lancet 2004; 363:474-81.
26. Health Organization. Guidelines for surveillance of drug resistance in tuberculosis. 4th Edition. WHO/HTM/TB.2009.422. Geneva, Switzerland: WHO, 2009.
27. Laserson KF, Thorpe LE, Leimane V, et al. Speaking the same language: treatment outcome definitions for multidrug-resistant tuberculosis. Int J Tuberc Lung Dis 2005; 9:640-5.
28. Hwang TJ, Dotsenko S, Jafarov A, et al. Safety and availability of clofazimine in the treatment of multidrug and extensively drug-resistant tuberculosis: analysis of published guidance and meta-analysis of cohort studies. BMJ Open 2014; 4:e004143.
29. Drugs.com. Clofazimine. Available at: http://www.drugs.com/cons/clofazimine.html. Accessed 1 July 2011.
30. Dey T, Brigden G, Cox H, et al. Outcomes of clofazimine for the treatment of drug-resistant tuberculosis: a systematic review and meta-analysis. J Antimicrob Chemother 2013; 68:284-93.
31. World Health Organization. 'Totally drug-resistant TB': a WHO consultation on the diagnostic definition and treatment options. Geneva, Switzerland: WHO, 2012.
32. Yawalkar SJ, Vischer W. Lamprene (clofazimine) in leprosy. Basic information. Lepr Rev 1979; 50:135-44.